Beyond Air Q3 net loss narrows, maintains guidance

Beyond Air

13/02/2026 12:40

Overview

Medical device firm's fiscal Q3 revenue rose 105% yr/yr to $2.2 mln

Net income and operating income for fiscal Q3 beat analyst expectations

Company signed agreement for XTL to acquire 85% of NeuroNOS

Outlook

Beyond Air maintains fiscal year 2026 revenue guidance of $8-10 mln

Company expects FDA clearance for second-generation LungFit PH by end of calendar 2026

Beyond Air expects cash runway into calendar 2027

Result Drivers

LUNGFIT PH DEMAND - Revenue growth driven by increased demand for LungFit PH in U.S. and international markets

VA MEDICAL CENTER SALE - Completed first sale of LungFit PH systems to a VA Medical Center, creating potential for future orders

GLOBAL DISTRIBUTION EXPANSION - Expanded LungFit PH distribution network to 40 countries, increasing market reach

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.85
Q3 Net Loss
Beat
-$7.63 mln
-$8.35 mln (4 Analysts)
Q3 Operating Loss
Beat
-$6.60 mln
-$7.95 mln (4 Analysts)
Q3 Gross Profit
$300,000
Q3 Operating Expenses
$6.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Beyond Air Inc is $8.50, about 733.3% above its February 12 closing price of $1.02

Press Release: ID:nGNX2dlmXt

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)